Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2024-11-29

Clinical Trial Update: MSD Belzutifan PAS

View source ↗

Summary

The belzutifan trial for von Hippel-Lindau disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Belzutifan (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Von Hippel Lindau Disease | Status: WITHDRAWN